INDV Company Profile and Key Details

NASDAQ : INDV

Indivior

$36.14

0.9261+2.63%

Open: 10:58 AM

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Indivior PLC (INDV) stock surged +2.36%, trading at $36.04 on NASDAQ, up from the previous close of $35.21. The stock opened at $35.21, fluctuating between $35.21 and $36.19 in the recent session.

Stock Snapshot

35.21

Prev. Close

4.5B

Market Cap

35.21

Day Low

36.78

P/E Ratio

0.98

EPS (TTM)

N/A

Cash Flow per Share

35.21

Open

124.86M

Number of Shares

36.19

Day High

88.08%

Free Float in %

N/A

Book Value

476.42K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Dec 19, 2025	35.54	36.02	35.02	35.21	22.6M
Dec 17, 2025	35.64	36.00	35.32	35.95	2.04M
Dec 16, 2025	35.09	35.56	34.91	35.38	3.41M
Dec 15, 2025	35.73	35.90	35.20	35.22	3.18M
Dec 12, 2025	36.30	36.55	35.54	35.55	2.82M
Dec 11, 2025	35.80	36.06	35.50	35.79	2.44M
Dec 10, 2025	36.01	36.57	35.40	35.45	2.68M
Dec 09, 2025	36.62	37.10	35.98	36.01	3.51M
Dec 08, 2025	37.72	38.00	36.42	36.60	8.1M
Dec 05, 2025	34.74	35.31	34.36	35.12	2.17M
Dec 04, 2025	33.81	34.77	33.50	34.60	964.74K
Dec 03, 2025	34.20	34.64	33.87	34.02	1.67M
Dec 02, 2025	34.00	34.32	33.51	34.00	1.15M
Dec 01, 2025	33.57	34.07	33.45	33.60	1.7M
Nov 28, 2025	33.15	34.03	33.00	33.60	718.86K
Nov 26, 2025	33.20	33.50	32.80	33.48	992.97K
Nov 25, 2025	33.35	33.64	32.54	33.10	1.57M
Nov 24, 2025	32.75	33.62	32.32	32.98	2.05M
Nov 21, 2025	31.57	33.00	31.23	32.75	2.23M
Nov 20, 2025	33.00	33.30	31.64	31.77	1.41M

Contact Details

North Chesterfield, VA 23235

United States

https://www.indivior.com 804 379 1090

About Company

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Stock Peers

NBIX

3.16+2.23%

Neurocrine Biosciences, Inc.$145.00 ITCI

Intra-Cellular Therapies, Inc.$131.87 ANIP

0.02+0.02%

ANI Pharmaceuticals, Inc.$82.85 LNTH

1.08+1.67%

Lantheus Holdings, Inc.$65.92 SUPN

2.2+4.46%

Supernus Pharmaceuticals, Inc.$51.48 COLL

-0.45-0.91%

Collegium Pharmaceutical, Inc.$48.88 HROW

1.84+4.13%

Harrow Health, Inc.$46.40 PAHC

-3.16-7.82%

Phibro Animal Health Corporation$37.25 PETQ

-0.01-0.03%

PetIQ, Inc.$30.98 AMPH

0.1+0.38%

Amphastar Pharmaceuticals, Inc.$26.60

Company Overview

Indivior PLC (NASDAQ:INDV) closed at $36.04 USD, gaining $0.83 (2.36%) from the previous close of $35.21. The stock is currently mid-range between its 52-week high and low $7.62 and $38.00. With a market capitalization of about $4.50 billion, Indivior PLC is classified as a mid-cap and shows market-like volatility (beta ~1.11). Key stats such as the average daily volume over the past year has been around 2.50 million shares, volume is running light vs its 52-week average. Headquartered in North Chesterfield, VA, Indivior PLC operates in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Led by CEO Joseph J. Ciaffoni, the company employs approximately 1,030 people and listed since December 29, 2014. Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally.

Technical Performance

Short-term trend indicators are bearishly aligned (SMA20 1.48%, SMA50 14.58%, SMA200 79.28%). The stock’s 14-day RSI is 62.55 (firm momentum), while the ATR of 1.07 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -7.34% below its high and over 362.07% above its low. Average 10-day trading volume of 6.81 million shares is significantly above the 3-month average of 2.39 million, indicating heightened recent market interest.

Valuation Metrics

Indivior PLC trades at a P/E ratio of 26.51, slightly below the S&P 500 average, with a price-to-sales ratio of 3.72 and a price-to-book ratio of -21.26 indicating negative book value, which may reflect financial stress. The P/FCF stands at 33.56, also above market averages.

Dividend & Fair Value

Indivior PLC last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$11.53. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Indivior PLC generated EPS of $1.00 over the past year. Five-year average earnings growth is -56.08%. Wall Street analysts project EPS growth of 24.43% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 5 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $41.00 to $13.00. The high target offers 16.44% upside. The low target suggests -63.08% downside. The mean target is $27.57. This offers -21.7% upside. Indivior PLC earnings surprise history is a consistent trend of beating forecasts. The quarter that ended October 30, 2025, missed forecasts by -14.32%. The prior quarter beat by 96.15%. Over the last six quarters, Apple has recorded several small beats. These include 10.0% in July 25, 2024.

Shareholding & Insider Activity

Indivior PLC has 124.77 million shares outstanding. The public float is 89.80 million shares, elevated short interest at 5.76% of float. This equals 7.12 million shares. The short ratio is 2.08 days. Institutional investors hold 91.47% of the float. Insiders own 3.88%.

Financial & Profitability Overview

Over the trailing twelve months, Indivior has not generated any revenue.
On valuation metrics, Indivior trades at a P/E of 26.51, P/S of 3.72 and P/B of -21.26. Liquidity is tight, with a current ratio of 0.96 and quick ratio of 0.79. Operationally, the company’s inventory turnover is 1.50 and cash conversion cycle is -10.33 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is -0.25, supported by a cash flow-to-debt ratio of 3.63.

Price Forecast & Outlook

Our AI price prediction model suggests that Indivior PLC stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 5.74%, with price expected at $37.23 by January 02, 2026, within a range of $36.33 to $38.08 3-Month Outlook: Projected fall of -12.04%, reaching $30.97 by March 19, 2026, with a range of $30.64 to $31.33. 1-Year Outlook: Projected loss of -3.69%, with price at $33.91 by December 18, 2026, within a range of $31.62 to $35.95.

Key Takeaways

Indivior PLC (NASDAQ:INDV) shares are up 183.27% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Indivior PLC trading at a premium to the broader market with a P/E of 26.51. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $24.33, suggesting -30.9% downside. Our AI forecast model points to short-term strength (5.74% over two weeks), a medium-term fall (-12.04% over three months), and a longer-term loss (-3.69% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Indivior PLC (INDV) stock price?

Indivior PLC (NASDAQ: INDV) stock price is $36.04 in the last trading session. During the trading session, INDV stock reached the peak price of $36.19 while $35.21 was the lowest point it dropped to. The percentage change in INDV stock occurred in the recent session was 2.36% while the dollar amount for the price change in INDV stock was $0.83.

INDV's industry and sector of operation?

The NASDAQ listed INDV is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector. Indivior PLC designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of INDV?

No Data

How INDV did perform over past 52-week?

INDV's closing price is 362.07% higher than its 52-week low of $7.62 where as its distance from 52-week high of $38.00 is -7.34%.

How many employees does INDV have?

Number of INDV employees currently stands at 1,030.

Link for INDV official website?

Official Website of INDV is: https://www.indivior.com

How do I contact INDV?

INDV could be contacted at phone 804 379 1090 and can also be accessed through its website. INDV operates from 10710 Midlothian Turnpike, North Chesterfield, VA 23235, United States.

How many shares of INDV are traded daily?

INDV stock volume for the day was 476.42K shares. The average number of INDV shares traded daily for last 3 months was 2.5M.

What is the market cap of INDV currently?

The market value of INDV currently stands at $4.50B with its latest stock price at $36.04 and 124.86M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	1030
Beta	1.11
Sales or Revenue	N/A
5Y Sales Change%	0.206%
Fiscal Year Ends	N/A
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic

INDV Company Profile and Key Details

Indivior

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Price Forecast & Outlook

Key Takeaways

Valuation Metrics